Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979501 | 0.90 | L3MBTL1 (0.53) | MEN1KMT2ASMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL1417419 | 0.86 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL6754368 | 0.83 | NPC1 (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL6766445 | 0.83 | MMP13 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6766898 | 0.81 | ENPP2 (0.61) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7984900 | 0.81 | L3MBTL1 (0.53) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL7977871 | 0.80 | HDAC6 (0.49) | MEN1KMT2ASMN1; SMN2ITGB3ITGA2B | |
| SCHEMBL31409517 | 0.79 | ESR1 (0.48) | MEN1KMT2APOLBCHRM5 | |
| SCHEMBL7984504 | 0.78 | CACNA1G (0.50) | MEN1KMT2ASMN1; SMN2HDAC6ALDH1A1 | |
| SCHEMBL7981151 | 0.78 | CACNA1G (0.48) | MEN1KMT2ASMN1; SMN2ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | NAHRA JOE (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038973-A1 | Treating osteoarthritis or rheumatoid arthritis | MMP13, MMP11, MMP9 | MEN1 2463/4885KMT2A 4041/4885SMN1; SMN2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.